Samarium Sm 153 Lexidronam Pentasodium
Samarium Sm-153 lexidronam pentasodium is the radioactive form of samarium lexidronam, in which samarium-153 is chelated to EDTMP for targeted bone palliation in patients with osteoblastic metastases from breast, prostate, and other cancers. The beta-emitting isotope concentrates in hydroxyapatite-rich metastatic bone lesions, delivering localized radiation to reduce skeletal pain and tumor burden. See samarium lexidronam pentasodium for complete pharmacological details.
分子量
695.9300 g/mol
TPSA
259.00 Ų
治疗领域
作用机制
Forms stable, water-soluble chelate complexes with specific metal ions, facilitating their excretion from the body through the kidneys. This reduces toxic metal burden in affected tissues.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Forms stable, water-soluble chelate complexes with specific metal ions, facilitating their excretion from the body through the kidneys. This reduces toxic metal burden in affected tissues.
SMILES
C(CN(CP(=O)([O-])[O-])CP(=O)([O-])[O-])N(CP(=O)([O-])[O-])CP(=O)([O-])[O-].[Na+].[Na+].[Na+].[Na+].[Na+].[153Sm+3]
InChI
InChI=1S/C6H20N2O12P4.5Na.Sm/c9-21(10,11)3-7(4-22(12,13)14)1-2-8(5-23(15,16)17)6-24(18,19)20;;;;;;/h1-6H2,(H2,9,10,11)(H2,12,13,14)(H2,15,16,17)(H2,18,19,20);;;;;;/q;5*+1;+3/p-8/i;;;;;;1+3
Molecular Formula
C6H12N2Na5O12P4Sm
HBD / HBA
- / 14
可旋转键数
7
重原子数
30
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
常见问题
Samarium Sm-153 lexidronam pentasodium is the radioactive form of samarium lexidronam, in which samarium-153 is chelated to EDTMP for targeted bone palliation in patients with osteoblastic metastases from breast, prostate, and other cancers. The beta-emitting isotope concentrates in hydroxyapatite-rich metastatic bone lesions, delivering localized radiation to reduce skeletal pain and tumor burden. See samarium lexidronam pentasodium for complete pharmacological details.
Forms stable, water-soluble chelate complexes with specific metal ions, facilitating their excretion from the body through the kidneys. This reduces toxic metal burden in affected tissues.
Yes, Samarium Sm 153 Lexidronam Pentasodium is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL2096660. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 9810246. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="samarium-sm-153-lexidronam-pentasodium"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/samarium-sm-153-lexidronam-pentasodium/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/samarium-sm-153-lexidronam-pentasodium/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/samarium-sm-153-lexidronam-pentasodium/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="samarium-sm-153-lexidronam-pentasodium"></drugfyi-drug>